NAALADL2: A Potential Drug Target and Biomarker for Alzheimer's Disease

Target Name: NAALADL2

NCBI ID: G254827

NAALADL2

NAALADL2: A Potential Drug Target and Biomarker for Alzheimer's Disease

Introduction

Alzheimer's disease (AD) is a neurodegenerative disorder that affects millions of people worldwide, leading to progressive memory loss, decline in cognitive function, and eventual death. The underlying cause of AD is the accumulation of neurofibrillary tangles and senile plaques in the brain, which disrupt the normal functioning of nerve cells. Currently, there is no cure for AD, and drug treatments primarily target symptoms rather than the underlying cause. As a result, the development of new drug targets and biomarkers has significant implications for the treatment of AD.

The NAALADL2 gene: A potential drug target

The NAALADL2 gene, located on chromosome 13, has been identified as a potential drug target for AD. The protein encoded by the NAALADL2 gene is N-acetylated alpha-linked acidic dipeptidase 2, a protein that has been shown to play a crucial role in the production and degradation of neurofibrillary tangles and senile plaques in the brain.

The neurofibrillary tangles and senile plaques are thought to be the hallmark hallmarks of AD, and the NAALADL2 gene has been shown to be involved in their formation and progression. Several studies have demonstrated that NAALADL2 is expressed in the brains of individuals with AD and that its expression levels are decreased in the prefrontal cortical regions of these individuals compared to age-matched controls. Additionally, individuals with Familial AD, a genetic form of AD, had lower expression levels of NAALADL2 in their brain tissue compared to age-matched controls.

The NAALADL2 gene also has been associated with the expression of other genes that are known to be involved in the development and progression of AD. For example, the gene has been shown to be involved in the production of the neurotransmitter glutamate, which is known to play a role in the development of neurofibrillary tangles. Additionally, the NAALADL2 gene has been shown to be involved in the production of the extracellular matrix protein, which is thought to contribute to the formation of senile plaques.

The potential benefits of targeting NAALADL2: A potential drug

Targeting NAALADL2 as a drug target could provide new treatment options for individuals with AD. By inhibiting the activity of NAALADL2, drug treatments could potentially reduce the formation of neurofibrillary tangles and senile plaques, leading to the improvement of cognitive function and the slowing of memory loss.

One potential drug that could target NAALADL2 is inhibitors of the enzyme-conjugated G protein-coupled receptor (EGFR), which is thought to play a role in the production of neurofibrillary tangles. EGFR is a transmembrane protein that is involved in a variety of cellular processes, including cell signaling, angiogenesis, and neurotransmission. Several studies have shown that inhibitors of EGFR, such as erlotinib and gefitinib, can be effective in treating EGFR-positive tumors, including AD.

Another potential drug that could target NAALADL2 is inhibitors of the protein kinase B (PKB), which is thought to play a role in the production of neurofibrillary tangles. PKB is a protein that is involved in cell signaling and is thought to contribute to the formation of neurofibrillary tangles. Several studies have shown that inhibitors of PKB, such as UA-1297-5873 and LY-862, can be effective in treating PKB-positive tumors, including AD.

In conclusion

NAALADL2 is a gene that has been identified as a potential drug target for

Protein Name: N-acetylated Alpha-linked Acidic Dipeptidase Like 2

Functions: May be catalytically inactive

The "NAALADL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NAALADL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets